Journal article · 2018 · Open access

Alzheimer's disease drug development pipeline: 2018

Jeffrey L. Cummings, Garam Lee, Aaron R. Ritter, Kate Zhong

Alzheimer s & Dementia Translational Research & Clinical Interventions, 4(1), 195–214 · Published 1 January 2018 · DOI 10.1016/j.trci.2018.03.009

Free PDFView at the publisherCite this paper

In brief

“Alzheimer's disease drug development pipeline: 2018” is a 2018 journal article by Jeffrey L. Cummings and 3 co-authors, published in Alzheimer s & Dementia Translational Research & Clinical Interventions. OpenAlex counts 729 citations as of 15 November 2026, which puts it in the top 2% of works published in 2018 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Alzheimer s & Dementia Translational Research & Clinical Interventions.

Citations
729
Most cited in
2020 (183)
Field-weighted impact
53.19
References
48
Authors
4

Abstract

INTRODUCTION: Treatments for Alzheimer's disease (AD) are needed due to the growing number of individuals with preclinical, prodromal, and dementia forms of AD. Drug development for AD therapies can be examined by inspecting the drug development pipeline as represented on clinicaltrials.gov. METHODS: Clinicaltrials.gov was assessed as of January 30, 2018 to determine AD therapies represented in phase I, phase II, and phase III. RESULTS: There are 112 agents in the current AD treatment pipeline. There are 26 agents in 35 trials in phase III, 63 agents in 75 trials in phase II, and 23 agents in 25 trials in phase I. A review of the mechanisms of actions of the agents in the pipeline shows that 63% are disease-modifying therapies, 22% are symptomatic cognitive enhancers, and 12% are symptomatic agents addressing neuropsychiatric and behavioral changes. Trials in phase III are larger and longer than phase II or phase I trials, particularly those involving disease-modifying agents. Comparison with the 2017 pipeline shows that there are four new agents in phase III, 14 in phase II, and eight in phase I. Inspection of the use of biomarkers as revealed on clinicaltrials.gov shows that amyloid biomarkers are used as entry criterion in 14 phase III disease-modifying agent trials and 17 disease-modifying agent trials in phase II. Twenty-one trials of disease-modifying agents in phase II did not require biomarker confirmation for AD at trial entry. DISCUSSION: The AD drug development pipeline is slightly larger in 2018 than in 2017. Trials increasingly include preclinical and prodromal populations. There is an increase in nonamyloid mechanisms of action for drugs in earlier phases of drug development. Biomarkers are increasingly used in AD drug development but are not used uniformly for AD diagnosis confirmation.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Cummings, J. L., Lee, G., Ritter, A. R., & Zhong, K. (2018). Alzheimer's disease drug development pipeline: 2018. Alzheimer s & Dementia Translational Research & Clinical Interventions, 4(1), 195–214. https://doi.org/10.1016/j.trci.2018.03.009

MLA 9

Cummings, Jeffrey L., et al. “Alzheimer's disease drug development pipeline: 2018.” Alzheimer s & Dementia Translational Research & Clinical Interventions, vol. 4, no. 1, 2018, pp. 195–214. https://doi.org/10.1016/j.trci.2018.03.009.

Chicago

Cummings, Jeffrey L., Garam Lee, Aaron R. Ritter, and Kate Zhong. 2018. “Alzheimer's disease drug development pipeline: 2018.” Alzheimer s & Dementia Translational Research & Clinical Interventions 4 (1): 195–214. https://doi.org/10.1016/j.trci.2018.03.009.

Harvard

Cummings, J. L. et al. (2018) ‘Alzheimer's disease drug development pipeline: 2018’, Alzheimer s & Dementia Translational Research & Clinical Interventions, 4(1), pp. 195–214. doi:10.1016/j.trci.2018.03.009.

IEEE

J. L. Cummings, G. Lee, A. R. Ritter, and K. Zhong, “Alzheimer's disease drug development pipeline: 2018,” Alzheimer s & Dementia Translational Research & Clinical Interventions, vol. 4, no. 1, pp. 195–214, 2018, doi: 10.1016/j.trci.2018.03.009.

BibTeX

@article{cummings2018alzheimer,
  title     = {{Alzheimer's disease drug development pipeline: 2018}},
  author    = {Cummings, Jeffrey L. and Lee, Garam and Ritter, Aaron R. and Zhong, Kate},
  journal   = {Alzheimer s \& Dementia Translational Research \& Clinical Interventions},
  year      = {2018},
  volume    = {4},
  number    = {1},
  pages     = {195--214},
  doi       = {10.1016/j.trci.2018.03.009},
  url       = {https://doi.org/10.1016/j.trci.2018.03.009}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201755
20184545
2019174174
2020183183
2021141141
20226464
20232525
20244141
20252929
20262020

Its field-weighted citation impact is 53.19: it has been cited 53.19 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments

  • Alzheimer's disease
  • drug development pipeline
  • clinical trials
  • disease-modifying therapy
  • amyloid biomarkers
  • prodromal Alzheimer's disease
  • preclinical Alzheimer's disease
  • neuropsychiatric symptoms

Work with this paper

Most-cited papers in Neuroscience

All highly cited Neuroscience papers

Questions about this paper

How do I cite this paper in APA style?

Cummings, J. L., Lee, G., Ritter, A. R., & Zhong, K. (2018). Alzheimer's disease drug development pipeline: 2018. Alzheimer s & Dementia Translational Research & Clinical Interventions, 4(1), 195–214. https://doi.org/10.1016/j.trci.2018.03.009

How many times has this paper been cited?

729 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at Alzheimer s & Dementia Translational Research & Clinical Interventions.

Who wrote this paper?

Jeffrey L. Cummings, Garam Lee, Aaron R. Ritter, Kate Zhong.

What is the DOI of this paper?

10.1016/j.trci.2018.03.009. The permanent link is https://doi.org/10.1016/j.trci.2018.03.009.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.